Cargando…
Meropenem Plasma and Interstitial Soft Tissue Concentrations in Obese and Nonobese Patients—A Controlled Clinical Trial
Background: This controlled clinical study aimed to investigate the impact of obesity on plasma and tissue pharmacokinetics of meropenem. Methods: Obese (body mass index (BMI) ≥ 35 kg/m(2)) and age-/sex-matched nonobese (18.5 kg/m(2) ≥ BMI ≤ 30 kg/m(2)) surgical patients received a short-term infusi...
Autores principales: | Simon, Philipp, Petroff, David, Busse, David, Heyne, Jana, Girrbach, Felix, Dietrich, Arne, Kratzer, Alexander, Zeitlinger, Markus, Kloft, Charlotte, Kees, Frieder, Wrigge, Hermann, Dorn, Christoph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767385/ https://www.ncbi.nlm.nih.gov/pubmed/33371322 http://dx.doi.org/10.3390/antibiotics9120931 |
Ejemplares similares
-
Similar Piperacillin/Tazobactam Target Attainment in Obese versus Nonobese Patients despite Differences in Interstitial Tissue Fluid Pharmacokinetics
por: Busse, David, et al.
Publicado: (2021) -
Tigecycline Soft Tissue Penetration in Obese and Non-obese Surgical Patients Determined by Using In Vivo Microdialysis
por: Dorn, Christoph, et al.
Publicado: (2022) -
Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients
por: Busse, David, et al.
Publicado: (2021) -
Linezolid Concentrations in Plasma and Subcutaneous Tissue are Reduced in Obese Patients, Resulting in a Higher Risk of Underdosing in Critically Ill Patients: A Controlled Clinical Pharmacokinetic Study
por: Simon, Philipp, et al.
Publicado: (2020) -
Measurement of soft tissue drug concentrations in morbidly obese and non-obese patients – A prospective, parallel group, open-labeled, controlled, phase IV, single center clinical trial()
por: Simon, P., et al.
Publicado: (2019)